GLP1 treatment is a breakthrough
BPC-157 is a 15-amino-acid synthetic peptide used in pre-clinical research models exploring tissue protection, gastric integrity, angiogenesis, tendon-to-bone healing, ligament remodeling, and inflammatory signalling
As of March 2025, the FDA has declared the semaglutide shortage over , which means compounding pharmacies are no longer authorized to produce compounded versions of the medication
[8] [9] It's important to note that observed bone changes during weight loss may reflect reduced mechanical loading and nutritional factors rather than direct medication effects on bone metabolism
Use LCLT if recovery limitations persist
The scientific evidence supporting probiotics for clinically meaningful weight loss remains limited and preliminary